Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report

Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimbara, Shiro, Imamura, Yoshinori, Yakushijin, Kimikazu, Higashime, Ako, Koyama, Taiji, Fujishima, Yoshimi, Funakoshi, Yohei, Toyoda, Masanori, Kiyota, Naomi, Matsuoka, Hiroshi, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783712/
https://www.ncbi.nlm.nih.gov/pubmed/33414911
http://dx.doi.org/10.3892/mco.2020.2192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783712/
https://www.ncbi.nlm.nih.gov/pubmed/33414911
http://dx.doi.org/10.3892/mco.2020.2192

Ejemplares similares